Volume | 566,503 |
|
|||||
News | - | ||||||
Day High | 33.50 | Low High |
|||||
Day Low | 32.255 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Collegium Pharmaceutical Inc | COLL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
32.64 | 32.255 | 33.50 | 33.14 | 32.43 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,919 | 566,503 | $ 32.94 | $ 18,658,113 | - | 20.83 - 40.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:04:20 | formt | 3,479 | $ 33.14 | USD |
Collegium Pharmaceutical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.06B | 31.96M | - | 566.77M | 48.16M | 1.51 | 22.01 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Collegium Pharmaceutical News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COLL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 34.09 | 34.55 | 32.075 | 33.22 | 482,650 | -0.95 | -2.79% |
1 Month | 37.80 | 38.60 | 30.42 | 33.57 | 553,922 | -4.66 | -12.33% |
3 Months | 37.52 | 40.95 | 30.42 | 36.22 | 466,808 | -4.38 | -11.67% |
6 Months | 25.59 | 40.95 | 25.21 | 34.20 | 446,252 | 7.55 | 29.50% |
1 Year | 21.73 | 40.95 | 20.83 | 29.60 | 377,799 | 11.41 | 52.51% |
3 Years | 23.93 | 40.95 | 14.04 | 24.18 | 341,608 | 9.21 | 38.49% |
5 Years | 11.49 | 40.95 | 10.01 | 22.09 | 371,696 | 21.65 | 188.42% |
Collegium Pharmaceutical Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol. |